Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

41.

Surgery and global health: a Lancet Commission.

Lancet.
Meara JG, Hagander L, Leather AJ.
| Jan 4, 2014
42.

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

Lancet.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM.
| Mar 15, 2014
43.

WHO's new guidelines for antiretroviral treatment - Authors' reply.

Lancet.
Mayer K, Beyrer C.
| Nov 30, 2013
45.

Challenges in clinical trial design for HIV-1 cure research.

Lancet.
Eyal N, Kuritzkes DR.
| Nov 2, 2013
46.

Male hypogonadism.

Lancet.
Basaria S.
| Apr 5, 2014
47.

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Lancet.
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J, Mendez G.
| Jan 4, 2014
48.

The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective.

Lancet.
Mahmood SS, Levy D, Vasan RS, Wang TJ.
| Mar 15, 2014
49.

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.

Lancet.
Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA.
| Dec 14, 2013
50.

Intracranial atherosclerosis.

Lancet.
Qureshi AI, Caplan LR.
| Mar 15, 2014
51.

Delirium in elderly people.

Lancet.
Inouye SK, Westendorp RG, Saczynski JS.
| Mar 8, 2014
52.

Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.

Lancet.
Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran D, Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzyllo W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL.
| Aug 17, 2013
53.

Adult obstructive sleep apnoea.

Lancet.
Jordan AS, McSharry DG, Malhotra A.
| Feb 22, 2014
54.

WHO's new HIV guidelines: opportunities and challenges.

Lancet.
Mayer K, Beyrer C.
| Jul 27, 2013
55.

Karyomegalic interstitial nephritis.

Lancet.
Zschiedrich S, Huber TB, Hildebrandt F, Mihatsch MJ, Wiech T.
| Dec 21, 2013
56.

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

Lancet.
Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ.
| Jul 6, 2013
57.

First-line treatment of indolent lymphoma: axing CHOP?

Lancet.
Jacobson CA, Freedman AS.
| Apr 6, 2013
58.

Metchnikoff and the microbiome.

Lancet.
Podolsky SH.
| Nov 24, 2012
59.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Lancet.
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, Samonigg H.
| Jan 26, 2013
60.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

Lancet.
Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS.
| Dec 8, 2012